Recent Pfizer Press Releases

  • 4/4/16 7:05 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today issued the following statement regarding the recently issued Department of Treasury Notice: “We are conducting a review of the U.S. Department of Treasury’s actions announced today. Prior to completing the review, we won’t speculate on any potential impact.” NO OFFER OR SOLICITATION This communication is not intended to and does not constitute an offermore...
  • 4/1/16 8:00 am EDT

    SPIRE-AI study evaluating bococizumab administered with pre-filled pen (autoinjector) met co-primary endpoints

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced that the Phase 3 SPIRE-AI (AutoInjector) trial of the investigational Proprotein Convertase Subtilisin Kexin type 9 inhibitor (PCSK9i) bococizumab administered with a pre-filled pen met its co-primary endpoints: percent change from baseline in low-density lipoprotein cholesterol (LDL-C) reduction at 12 weeks compared to placebo and proportion of patients successfully operating the pre-filled pen. The SPIRE-AI trial is themore...
  • 3/31/16 4:29 pm EDT
    NEW YORK--(BUSINESS WIRE)--A false press release related to drug pricing and linking to a fake web site was anonymously issued earlier today. It was erroneously attributed to Pfizer and should be disregarded. Pfizer is investigating this matter and evaluating its legal options against the parties responsible. Pfizer is committed to engaging in an honest discussion and real dialogue about the issues that matter to patients. more...
  • 3/30/16 12:41 pm EDT
    • The request was fully anticipated as part of the regulatory process
    • Pfizer and Allergan continue to expect the transaction to close in the second half of 2016
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Allergan plc (NYSE:AGN) today announced that the companies have received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to their previously announced pending combination. The request for information from the FTC, often referred to as a “second request,” was fully anticipated as part of the regulatory process under the Hart-Scott-Rodino Antitrust Improvements Act of 1976more...
  • 3/30/16 7:45 am EDT

    Seventeen abstracts to be presented, including new analyses from the Phase 3 ARISTOTLE and AMPLIFY clinical studies and from real-world databases

    PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today that 17 abstracts will be presented at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16), to be held April 2-4 in Chicago, IL. The new analyses contribute to the Bristol-Myers Squibb and Pfizer Alliance’s body of evidence on the use of Eliquis to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF)more...
  • 3/23/16 4:15 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for XELJANZ® (tofacitinib citrate) 5 mg tablets twice daily for the treatment of patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). The EMA will now initiate its review of the XELJANZ MAA. Thismore...
  • 3/22/16 8:30 am EDT

    By Pooling Knowledge and Resources From Academia, Government, and Industry Partners, the Consortium Will Evaluate Human Immune Responses with the Goal to Potentially Speed Vaccines and Immunotherapeutic Development

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it will join the Human Vaccines Project (the Project), a public-private consortium focused on cross-sector collaboration to identify human immune responses associated with optimal vaccine protection. Insights gained will guide the development of potentially improved vaccines against diseases such as influenza, dengue, HIV and other infectious illnesses as well as cancer. “Over the last decade, we’more...
  • 3/18/16 11:00 am EDT

    Detailed Results from OCTAVE Induction 1 and 2 Presented During Oral Session at 11th Congress of ECCO

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the oral presentation of detailed results from the first two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program at the 11th Congress of ECCO. Results from OCTAVE Induction 1 and OCTAVE Induction 2, evaluating the efficacy and safety of oral tofacitinib 10 mg twice daily (BID) in inducing remission in adult patients with moderately to severely activemore...
  • 3/16/16 8:00 am EDT

    Seven Abstracts, Including Pivotal Phase 3 Data in Ulcerative Colitis, Accepted for Presentation

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that seven abstracts reporting on new research for tofacitinib in ulcerative colitis (UC) and Crohn’s disease will be presented at the 11th Congress of ECCO, which will be held March 16-19 in Amsterdam, The Netherlands. Among the abstracts are detailed results from two pivotal Phase 3 studies from the Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) program. Tofacitinib is being studiedmore...
  • 3/15/16 1:53 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) released today its 2015 integrated annual review, an in-depth look into the company’s financial, social and environmental performance. 2015 was marked by breakthrough scientific research, collaborations and partnerships. In the review, our scientists, researchers and business leaders offer in-depth looks at their projects and how they are working to discover and develop potential new medicines and vaccines to improvemore...